{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:32Z","timestamp":1792683032590,"version":"4.5.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell\u2013redirecting therapies have transformed the treatment of relapsed\/refractory multiple myeloma (RRMM) but are associated with substantial infection risk. We systematically reviewed infections after CAR T-cell therapy and bispecific antibodies (BsAbs), focusing on incidence, timing, pathogens, risk factors, and prevention. Following PRISMA guidelines, we searched PubMed through May 22, 2026, and included studies reporting infectious outcomes in RRMM patients treated with CAR-T cells or BsAbs. A total of 123 predominantly early-phase, non-comparative studies were analyzed. Across BCMA-directed CAR-T products and BsAbs, infections were frequent (any-grade incidence\u2009~\u200940\u201380%), with highest risk early after CAR-T infusion and during the first months of BsAb therapy. Grade\u2009\u2265\u20093 infections were common and exceeded 50% in several BsAb cohorts. Fatal infections were less frequent but occurred across both CAR-T and BsAb studies. In randomized CAR-T trials, grade 5 infections represented a substantial proportion of treatment-related deaths. Talquetamab showed lower infection rates (47\u201355%) but relevant mucocutaneous toxicity. Viral and bacterial pathogens predominated; CMV reactivation, invasive fungal infections, and Pneumocystis jirovecii pneumonia, particularly without prophylaxis, were also reported. Risk factors included neutropenia, corticosteroid\/tocilizumab exposure, and hypogammaglobulinemia. Antiviral and Pneumocystis jirovecii pneumonia (PJP) prophylaxis and, most notably, immunoglobulin replacement reduced infections, though residual risk persisted. Real-world data suggest higher infection-related healthcare use and mortality with BsAbs versus CAR-T therapy. Extended dosing intervals may reduce infections, particularly severe infections, while preserving efficacy. Infectious toxicity remains a key limitation. Risk is particularly high with BCMA-targeted therapies and continuous BsAb administration. Tailored prophylaxis, early immunoglobulin replacement, and response-adapted treatment strategies, including extended dosing intervals, may improve safety and outcomes.<\/jats:p>","DOI":"10.1007\/s00277-026-07140-8","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:21:04Z","timestamp":1781817664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review"],"prefix":"10.1007","volume":"105","author":[{"given":"Magdalena","family":"Benda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Gunsilius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Strassl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Theresa","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"12","key":"7140_CR1","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1182\/bloodadvances.2024012871","volume":"8","author":"AJ Howard","year":"2024","unstructured":"Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz M, Mailankody S et al (2024) Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies. Blood Adv 8(12):3246\u20133253","journal-title":"Blood Adv"},{"issue":"1","key":"7140_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B et al (2022) Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol 15(1):78","journal-title":"J Hematol Oncol"},{"issue":"1","key":"7140_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","volume":"14","author":"K Nath","year":"2024","unstructured":"Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N et al (2024) Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood cancer J 14(1):88","journal-title":"Blood cancer J"},{"key":"7140_CR4","unstructured":"Matthew J, Page JEM, Patrick M, Bossuyt I, Boutron TC, Hoffmann CD, Mulrow L, Shamseer, Lesley A, Stewart P, Tetzlaff EA, Akl SE, Brennan R, Chou J, Glanville SE, Grimshaw Asbj\u00f8rn, Hr\u00f3bjartsson MM, Lalu T, Li EA, McDonald S, McGuinness, Luke A, McRobbie, Matthew JM, Naden Gabriel Rada, Paul Shekelle, James Thomas, Andrea C Tricco, Vivian A Welch, Penny Whiting, David Moher. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ2021 [Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71"},{"key":"7140_CR5","unstructured":"https:\/\/casp-uk.net\/casp-tools-checklists\/"},{"key":"7140_CR6","unstructured":"https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials"},{"key":"7140_CR7","unstructured":"https:\/\/methods.cochrane.org\/bias\/risk-bias-non-randomized-studies-interventions"},{"issue":"6","key":"7140_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A et al (2022) Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 387(6):495\u2013505","journal-title":"N Engl J Med"},{"issue":"10301","key":"7140_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A et al (2021) Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet (London England) 398(10301):665\u2013674","journal-title":"Lancet (London England)"},{"issue":"6","key":"7140_CR10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A et al (2024) Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer 130(6):886\u2013900","journal-title":"Cancer"},{"issue":"1","key":"7140_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2024","unstructured":"Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A et al (2024) Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv 8(1):194\u2013206","journal-title":"Blood Adv"},{"issue":"23","key":"7140_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S et al (2024) Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood 144(23):2375\u20132388","journal-title":"Blood"},{"issue":"2","key":"7140_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12185-024-03884-z","volume":"121","author":"T Ishida","year":"2025","unstructured":"Ishida T, Kuroda Y, Matsue K, Komeno T, Ishiguro T, Ishikawa J et al (2025) A Phase 1\/2 study of teclistamab, a humanized BCMA \u00d7 CD3 bispecific Ab in Japanese patients with relapsed\/refractory MM. Int J Hematol 121(2):222\u2013231","journal-title":"Int J Hematol"},{"issue":"1","key":"7140_CR14","doi-asserted-by":"publisher","first-page":"e35665","DOI":"10.1002\/cncr.35665","volume":"131","author":"Z Cai","year":"2025","unstructured":"Cai Z, Xia Z, He A-L, Dong Y-J, Wang Y, Liao A et al (2025) Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1. Cancer 131(1):e35665","journal-title":"Cancer"},{"issue":"3","key":"7140_CR15","doi-asserted-by":"publisher","first-page":"308e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H et al (2024) Safety and Efficacy of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Real-World Experience. Transplantation Cell therapy 30(3):308e1\u2013e13","journal-title":"Transplantation Cell therapy"},{"issue":"2","key":"7140_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A et al (2024) Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 38(2):365\u2013371","journal-title":"Leukemia"},{"key":"7140_CR17","doi-asserted-by":"crossref","unstructured":"Kawasaki Y, Steele AP, Rosenberg A, Guglielmo J (2024) Safety outcomes of teclistamab accelerated dose escalation. J Oncol Pharm practice: official publication Int Soc Oncol Pharm Practitioners. :10781552241268429","DOI":"10.1177\/10781552241268429"},{"issue":"1","key":"7140_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan CR, Asoori S, Huang C-Y, Brunaldi L, Popat R, Kastritis E et al (2025) Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood cancer J 15(1):53","journal-title":"Blood cancer J"},{"key":"7140_CR19","doi-asserted-by":"crossref","unstructured":"Perrot A, Hulin C, Boumendil A, Manjra H, Leveque A, Croizier C et al (2024) Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program. Haematologica","DOI":"10.3324\/haematol.2024.286118"},{"issue":"1","key":"7140_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V et al (2024) Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood cancer J 14(1):35","journal-title":"Blood cancer J"},{"key":"7140_CR21","unstructured":"Ariane B, St\u00e9phanie H, Bertrand A, Isabelle M, Laure D (2025) Immunosubstitution of patients with refractory multiple myeloma treated with Teclistamab, a bispecific antibody. Annales pharmaceutiques francaises"},{"issue":"6","key":"7140_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/2643-3230.BCD-24-0354","volume":"6","author":"BM Razzo","year":"2025","unstructured":"Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P et al (2025) Real-World Experience with Teclistamab for Relapsed\/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium. Blood Cancer Discov 6(6):561\u2013571","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"7140_CR23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.pharma.2025.04.008","volume":"83","author":"A Bros","year":"2025","unstructured":"Bros A, Harel S, Arnulf B, Madelaine I, Deville L (2025) [Immunosubstitution of patients with refractory multiple myeloma treated with teclistamab, a bispecific antibody]. Ann Pharm Fr 83(5):1001\u20131010","journal-title":"Ann Pharm Fr"},{"key":"7140_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cancers17213569","volume":"17","author":"J Snyder","year":"2025","unstructured":"Snyder J, Atrash S, Paul B, Khan AM, Habib A, Shaikh H et al (2025) Teclistamab Dosing Strategies in Relapsed\/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals. Cancers (Basel) 17:21","journal-title":"Cancers (Basel)"},{"issue":"8","key":"7140_CR25","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1007\/s00277-025-06529-1","volume":"104","author":"M Stork","year":"2025","unstructured":"Stork M, Radocha J, Mihalyova J, Spicka I, Pika T, Jungova A et al (2025) De-escalated Teclistamab dosing in relapsed\/refractory multiple myeloma: Czech myeloma group real-world evidence analysis. Ann Hematol 104(8):4141\u20134147","journal-title":"Ann Hematol"},{"key":"7140_CR26","doi-asserted-by":"crossref","unstructured":"Yi JH, Lee JH, Jung SH, Lee JH, Lee JY, Kim K et al (2025) Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea. Cancer Res Treat","DOI":"10.4143\/crt.2025.399"},{"key":"7140_CR27","doi-asserted-by":"crossref","unstructured":"Smits F, Groen K, Korst C, Frerichs KA, Kuipers I, Kruyswijk S et al (2026) Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab. Blood Cancer J. ;16(1)","DOI":"10.1038\/s41408-026-01451-9"},{"key":"7140_CR28","doi-asserted-by":"crossref","unstructured":"Ssentongo P, Guare EG, Song C, Inoue Y, Sandhu M, Annageldiyev C et al (2026) Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab. Curr Oncol. ;33(3)","DOI":"10.3390\/curroncol33030154"},{"key":"7140_CR29","doi-asserted-by":"crossref","unstructured":"Cheema H, Shrestha A, Naqvi S, Muttineni S, Dronavalli S, Alrawabdeh J et al (2026) Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients. Blood Cancer J. ;16(1)","DOI":"10.1038\/s41408-026-01593-w"},{"key":"7140_CR30","unstructured":"Luciano JC, MDhoo\u2014 NJ, Bahlis MD, Aurore Perrot MD, Nooka PD, Jin Lu MDMPH, Charlotte Pawlyn MD, Mina MBBCPDR, Gaston Caeiro MD, Alain Kentos MD, Vania Hungria MD, Donna Reece MDPD, Niu MDT, Anne MD, Mylin K, Charlotte MDPD, Hansen T, Teipel PDR, Britta Besemer MD, Meletios MD, Dimopoulos A, Zamagni MDE, Yoshihara MDS, Kim MDK, Chang Ki Min MD, Paul Geerts MD, Van Leeuwen-Segarceanu MDPDE, Agata Tyczynska MDPD, Reguera MDPDJL, Johansson PDM, Markus Hansson MD, Mehmet Turgut MDPD, Grey MDM, Surbhi Sidana MD, Rodriguez-Otero MDP, Martinez-Lopez MDPDJ, Hashmi MDPDH, Carson MDR, Kobos MDR, Sun MDW, Lantz MDPDK, Seifert PDA, Briseno-Toomey PDD, Lisa MSN O\u2019Rourke, M.S.N., Rubin M, Vieyra PDD, Kang PDL (2025) Ph.D., and Maria Victoria Mateos, M.D., Ph.D., for the MajesTEC-3 Trial Investigators. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine"},{"issue":"9","key":"7140_CR31","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267","journal-title":"Nat Med"},{"issue":"10","key":"7140_CR32","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M et al (2023) Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med 29(10):2570\u20132576","journal-title":"Nat Med"},{"issue":"7","key":"7140_CR33","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J et al (2024) Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. HemaSphere 8(7):e136","journal-title":"HemaSphere"},{"issue":"9","key":"7140_CR34","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jjco\/hyae068","volume":"54","author":"S Iida","year":"2024","unstructured":"Iida S, Ito S, Yokoyama H, Ishida T, Nagai Y, Handa H et al (2024) Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3. Jpn J Clin Oncol 54(9):991\u20131000","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"7140_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","volume":"14","author":"F Malard","year":"2024","unstructured":"Malard F, Bobin A, Labopin M, Karlin L, Frenzel L, Roussel M et al (2024) Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood cancer J 14(1):219","journal-title":"Blood cancer J"},{"issue":"1","key":"7140_CR36","doi-asserted-by":"publisher","first-page":"e70130","DOI":"10.1002\/jcph.70130","volume":"66","author":"P Soltantabar","year":"2026","unstructured":"Soltantabar P, Hibma J, Wang D, Conte U, Hickman A, Elmeliegy M (2026) Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma. J Clin Pharmacol 66(1):e70130","journal-title":"J Clin Pharmacol"},{"key":"7140_CR37","doi-asserted-by":"crossref","unstructured":"Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M et al (2026) Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. ;16(1)","DOI":"10.1038\/s41408-026-01477-z"},{"issue":"22","key":"7140_CR38","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A et al (2024) Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma. J Clin oncology: official J Am Soc Clin Oncol 42(22):2702\u20132712","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"2","key":"7140_CR39","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","volume":"26","author":"HC Lee","year":"2026","unstructured":"Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A et al (2026) Linvoseltamab in Patients With Relapsed\/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Clin Lymphoma Myeloma Leuk 26(2):e201\u2013e12.e8.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"7140_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C et al (2020) Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin oncology: official J Am Soc Clin Oncol 38(8):775\u2013783","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"7140_CR41","doi-asserted-by":"crossref","unstructured":"Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A et al (2026) Phase 1\/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed\/refractory multiple myeloma. Blood","DOI":"10.1182\/blood.2025032044"},{"issue":"3","key":"7140_CR42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41375-025-02841-x","volume":"40","author":"N Bar","year":"2026","unstructured":"Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L et al (2026) Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study. Leukemia 40(3):481\u2013490","journal-title":"Leukemia"},{"issue":"24","key":"7140_CR43","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P et al (2022) Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 387(24):2232\u20132244","journal-title":"N Engl J Med"},{"issue":"4","key":"7140_CR44","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A et al (2025) Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol 12(4):e269\u2013e81","journal-title":"Lancet Haematol"},{"issue":"3","key":"7140_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s12185-025-03991-5","volume":"122","author":"S Iida","year":"2025","unstructured":"Iida S, Sunami K, Ito S, Yuda J, Fujikawa E, Takamoto M et al (2025) Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed\/refractory MM. Int J Hematol 122(3):421\u2013433","journal-title":"Int J Hematol"},{"issue":"4","key":"7140_CR46","doi-asserted-by":"publisher","first-page":"e70114","DOI":"10.1002\/hem3.70114","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M et al (2025) A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma. HemaSphere 9(4):e70114","journal-title":"HemaSphere"},{"issue":"10","key":"7140_CR47","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/03007995.2024.2387183","volume":"40","author":"C Schinke","year":"2024","unstructured":"Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T et al (2024) Real-world experience with clinical management of talquetamab in relapsed\/refractory multiple myeloma: a qualitative study of US healthcare providers. Curr Med Res Opin 40(10):1705\u20131711","journal-title":"Curr Med Res Opin"},{"issue":"22","key":"7140_CR48","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/bloodadvances.2025016613","volume":"9","author":"C Schinke","year":"2025","unstructured":"Schinke C, Rodriguez-Otero P, van de Donk N, Lipe B, Lavi N, Rasche L et al (2025) Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1. Blood Adv 9(22):5752\u20135762","journal-title":"Blood Adv"},{"issue":"1","key":"7140_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-025-01386-7","volume":"15","author":"S Al Hadidi","year":"2025","unstructured":"Al Hadidi S, Szabo A, Mohan Lal B, Bag A, Zhen S, Ogunsesan Y et al (2025) Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J 15(1):196","journal-title":"Blood Cancer J"},{"key":"7140_CR50","doi-asserted-by":"crossref","unstructured":"Janakiram M, Tan CR, Mian H, Huang CY, Popat R, Mart\u00ednez-Lopez J et al (2026) Real-World Evaluation of Talquetamab for the Treatment of Relapsed\/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis. Am J Hematol","DOI":"10.1002\/ajh.70376"},{"issue":"Supplement 1","key":"7140_CR51","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1182\/blood-2022-157547","volume":"140","author":"AM Lesokhin","year":"2022","unstructured":"Lesokhin AM, Richter J, Trudel S, Cohen AD, Spencer A, Forsberg PA et al (2022) Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study. Blood 140(Supplement 1):4415\u20134417","journal-title":"Blood"},{"issue":"Supplement 1","key":"7140_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG et al (2021) Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. Blood 138(Supplement 1):157","journal-title":"Blood"},{"issue":"2","key":"7140_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min C-K et al (2025) Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 392(2):138\u2013149","journal-title":"N Engl J Med"},{"issue":"1","key":"7140_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2514752","volume":"394","author":"S Kumar","year":"2026","unstructured":"Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H et al (2026) Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. N Engl J Med 394(1):51\u201361","journal-title":"N Engl J Med"},{"issue":"6","key":"7140_CR55","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","volume":"30","author":"A Jourdes","year":"2024","unstructured":"Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G et al (2024) Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study. Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis 30(6):764\u2013771","journal-title":"Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis"},{"issue":"12","key":"7140_CR56","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14712598.2023.2273276","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, Zhang P, Sun H, Han L, Jiang Z, Yu J (2023) Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting. Expert Opin Biol Ther 23(12):1193\u20131195","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"7140_CR57","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","volume":"15","author":"M Mohan","year":"2025","unstructured":"Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A et al (2025) Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood cancer J 15(1):74","journal-title":"Blood cancer J"},{"issue":"6","key":"7140_CR58","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A et al (2023) IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood cancer discovery 4(6):440\u2013451","journal-title":"Blood cancer discovery"},{"issue":"8","key":"7140_CR59","doi-asserted-by":"publisher","first-page":"e7048","DOI":"10.1002\/cam4.7048","volume":"13","author":"K Uttervall","year":"2024","unstructured":"Uttervall K, T\u00e4tting L, Lemonakis K, Majd M, Crafoord J, Olsson M et al (2024) Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden. Cancer Med 13(8):e7048","journal-title":"Cancer Med"},{"issue":"1","key":"7140_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","volume":"13","author":"BZ Sim","year":"2023","unstructured":"Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW (2023) Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood cancer J 13(1):34","journal-title":"Blood cancer J"},{"issue":"12","key":"7140_CR61","doi-asserted-by":"publisher","first-page":"E349","DOI":"10.1002\/ajh.27071","volume":"98","author":"A Contejean","year":"2023","unstructured":"Contejean A, Janssen C, Orsini-Piocelle F, Zecchini C, Charlier C, Chouchana L (2023) Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study. Am J Hematol 98(12):E349\u2013E53","journal-title":"Am J Hematol"},{"key":"7140_CR62","doi-asserted-by":"crossref","unstructured":"Kowalski A, Lykon J, Diamond BT, Coffey DG, Kaddoura M, Maura F et al (2025) Tocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific Antibodies. Blood Adv","DOI":"10.1182\/bloodadvances.2025016911"},{"issue":"2","key":"7140_CR63","doi-asserted-by":"publisher","first-page":"74e1","DOI":"10.1016\/j.jtct.2024.11.010","volume":"31","author":"S Choi","year":"2025","unstructured":"Choi S, Byun JM, Park S-S, Han J, Oh S, Jung S et al (2025) Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed\/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study. Transplantation Cell therapy 31(2):74e1\u2013e11","journal-title":"Transplantation Cell therapy"},{"issue":"20","key":"7140_CR64","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.3346\/jkms.2025.40.e86","volume":"40","author":"T Park","year":"2025","unstructured":"Park T, Jang S, Koh Y, Shin D-Y, Yoon S-S, Lee CM et al (2025) Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies. J Korean Med Sci 40(20):e86","journal-title":"J Korean Med Sci"},{"issue":"6","key":"7140_CR65","doi-asserted-by":"publisher","first-page":"477e1","DOI":"10.1016\/j.jtct.2021.03.004","volume":"27","author":"R Banerjee","year":"2021","unstructured":"Banerjee R, Marsal J, Huang C-Y, Lo M, Thiruvengadam SK, Kennedy VE et al (2021) Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplantation Cell therapy 27(6):477e1\u2013e7","journal-title":"Transplantation Cell therapy"},{"issue":"2","key":"7140_CR66","first-page":"656","volume":"111","author":"L Cani","year":"2026","unstructured":"Cani L, Scott SA, Roberts D, Joseph NS, Hofmeister CC, Gupta VA et al (2026) Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience. Haematologica 111(2):656\u2013664","journal-title":"Haematologica"},{"issue":"2","key":"7140_CR67","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11523-026-01209-0","volume":"21","author":"YC Wang","year":"2026","unstructured":"Wang YC, Li PH, Lin CH, Su YC, Teng CJ (2026) Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study. Target Oncol 21(2):227\u2013235","journal-title":"Target Oncol"},{"issue":"10","key":"7140_CR68","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood.2025029572","volume":"147","author":"T Jelinek","year":"2026","unstructured":"Jelinek T, Zihala D, Zabaleta A, Kostopoulos IV, Soucek O, Venglar O et al (2026) Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs. Blood 147(10):1070\u20131082","journal-title":"Blood"},{"issue":"2","key":"7140_CR69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.clml.2025.10.024","volume":"26","author":"B Piron","year":"2026","unstructured":"Piron B, Rodrigo L, Tessoulin B, Gastinne T, Dubruille V, Letailleur V et al (2026) Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies. Clin Lymphoma Myeloma Leuk 26(2):115\u201322e6","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"7140_CR70","doi-asserted-by":"publisher","first-page":"ofaf672","DOI":"10.1093\/ofid\/ofaf672","volume":"12","author":"I Bilbao","year":"2025","unstructured":"Bilbao I, Ans\u00f3n M, Villar S, Pineda I, G\u00e1rriz L, Pina-S\u00e1nchez M et al (2025) Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies. Open Forum Infect Dis 12(11):ofaf672","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"7140_CR71","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/bloodadvances.2025019231","volume":"10","author":"CR Tan","year":"2026","unstructured":"Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S et al (2026) Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis. Blood Adv 10(9):2937\u20132946","journal-title":"Blood Adv"},{"issue":"1","key":"7140_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12967-025-06140-y","volume":"23","author":"Z Li","year":"2025","unstructured":"Li Z, Zhang F, Jin X, Zhuang J (2025) Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab. J translational Med 23(1):117","journal-title":"J translational Med"},{"issue":"3","key":"7140_CR73","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3324\/haematol.2023.283590","volume":"109","author":"L Hammons","year":"2024","unstructured":"Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B et al (2024) The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica 109(3):906\u2013914","journal-title":"Haematologica"},{"issue":"17","key":"7140_CR74","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.2025029773","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D et al (2025) Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood 146(17):2063\u20132072","journal-title":"Blood"},{"issue":"8","key":"7140_CR75","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S et al (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"11","key":"7140_CR76","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A et al (2023) Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin oncology: official J Am Soc Clin Oncol 41(11):2087\u20132097","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"9","key":"7140_CR77","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D et al (2023) Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med 29(9):2286\u20132294","journal-title":"Nat Med"},{"issue":"5","key":"7140_CR78","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3324\/haematol.2023.283888","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, Avila G et al (2024) Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica 109(5):1514\u20131524","journal-title":"Haematologica"},{"issue":"17","key":"7140_CR79","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","volume":"8","author":"NM Kalariya","year":"2024","unstructured":"Kalariya NM, Hildebrandt MAT, Hansen DK, Sidana S, Khouri J, Ferreri CJ et al (2024) Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv 8(17):4679\u20134688","journal-title":"Blood Adv"},{"issue":"5","key":"7140_CR80","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","volume":"117","author":"D Minakata","year":"2023","unstructured":"Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S et al (2023) Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol 117(5):729\u2013737","journal-title":"Int J Hematol"},{"issue":"5","key":"7140_CR81","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","volume":"9","author":"MR Gaballa","year":"2025","unstructured":"Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ et al (2025) BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv 9(5):1171\u20131180","journal-title":"Blood Adv"},{"issue":"1","key":"7140_CR82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW et al (2023) Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood cancer J 13(1):117","journal-title":"Blood cancer J"},{"issue":"4","key":"7140_CR83","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/bjh.19302","volume":"204","author":"D Dima","year":"2024","unstructured":"Dima D, Rashid A, Davis JA, Shune L, Abdallah A-O, Li H et al (2024) Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. Br J Haematol 204(4):1293\u20131299","journal-title":"Br J Haematol"},{"key":"7140_CR84","doi-asserted-by":"crossref","unstructured":"Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M et al (2025) Standard-of-Care Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma. A CIBMTR Analysis. Blood","DOI":"10.1182\/blood.2024026216"},{"key":"7140_CR85","doi-asserted-by":"crossref","unstructured":"Trando A, Ghamsari F, Yeung P, Costello C, Saunders I, Jeong A-R (2024) Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: A Single-Institution Experience. Biomedicines. ;13(1)","DOI":"10.3390\/biomedicines13010036"},{"issue":"24","key":"7140_CR86","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H et al (2022) Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv 6(24):6109\u20136119","journal-title":"Blood Adv"},{"key":"7140_CR87","doi-asserted-by":"crossref","unstructured":"Kikuchi T, Watanabe M, Tsukada N, Matsumoto C, Nomura-Yogo M, Kunisada K et al (2025) Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed\/Refractory Multiple Myeloma. Transpl Infect disease: official J Transplantation Soc. :e70040","DOI":"10.1111\/tid.70040"},{"issue":"7","key":"7140_CR88","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/bloodadvances.2024014970","volume":"9","author":"OS Akhtar","year":"2025","unstructured":"Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S et al (2025) Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv 9(7):1587\u20131592","journal-title":"Blood Adv"},{"issue":"6","key":"7140_CR89","doi-asserted-by":"publisher","first-page":"630e1","DOI":"10.1016\/j.jtct.2024.03.003","volume":"30","author":"L Caillot","year":"2024","unstructured":"Caillot L, Sleiman E, Lafon I, Chretien M-L, Gueneau P, Payssot A et al (2024) Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed\/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. Transplantation Cell therapy 30(6):630e1\u2013e8","journal-title":"Transplantation Cell therapy"},{"issue":"1","key":"7140_CR90","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12885-023-10824-3","volume":"23","author":"DA Sanoyan","year":"2023","unstructured":"Sanoyan DA, Seipel K, Bacher U, Kronig M-N, Porret N, Wiedemann G et al (2023) Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients. BMC Cancer 23(1):345","journal-title":"BMC Cancer"},{"issue":"23","key":"7140_CR91","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S et al (2024) Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood 144(23):2389\u20132401","journal-title":"Blood"},{"issue":"10297","key":"7140_CR92","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet (London England) 398(10297):314\u2013324","journal-title":"Lancet (London England)"},{"issue":"6","key":"7140_CR93","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"J-Q Mi","year":"2023","unstructured":"Mi J-Q, Zhao W, Jing H, Fu W, Hu J, Chen L et al (2023) Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed\/Refractory Multiple Myeloma (CARTIFAN-1). J Clin oncology: official J Am Soc Clin Oncol 41(6):1275\u20131284","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"1","key":"7140_CR94","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L et al (2025) Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood 145(1):85\u201397","journal-title":"Blood"},{"issue":"4","key":"7140_CR95","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V et al (2023) Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 389(4):335\u2013347","journal-title":"N Engl J Med"},{"issue":"12","key":"7140_CR96","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1111\/cas.15556","volume":"113","author":"M Ri","year":"2022","unstructured":"Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T et al (2022) Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Cancer Sci 113(12):4267\u20134276","journal-title":"Cancer Sci"},{"issue":"12","key":"7140_CR97","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.clml.2023.08.012","volume":"23","author":"M Htut","year":"2023","unstructured":"Htut M, Dhakal B, Cohen AD, Martin T, Berdeja JG, Usmani SZ et al (2023) Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Clin lymphoma myeloma Leuk 23(12):882\u2013888","journal-title":"Clin lymphoma myeloma Leuk"},{"issue":"2","key":"7140_CR98","doi-asserted-by":"publisher","first-page":"71e1","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi M, Elsallab M, Lunning MA, Holstein SA, Sharma S, Trinh JQ et al (2025) Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. Transplantation Cell therapy 31(2):71e1\u2013e14","journal-title":"Transplantation Cell therapy"},{"key":"7140_CR99","unstructured":"Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW et al Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma Infection risk associated with teclistamab in relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence. Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed\/refractory multiple myeloma: a meta-analysis of interventional and real-world studies. The Efficacy and Safety of B-Cell Maturation Antigen (BCMA) Antibody-Drug Conjugates (ADC) in Development against Cancer: A Systematic Review Safety and Efficacy of Bispecific Antibody Treatment in Relapsed\/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials. LID\u2009\u2013\u200910.3390\/cancers17172727 [doi] LID\u2009\u2013\u20092727. Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials. The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis. The Role of Bispecific Antibodies in Relapsed\/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review. LID\u2009\u2013\u200910.1002\/ajh.70312 [doi]. Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis. LID - S2152-2650(26)00066\u2009\u2013\u20092 [pii] LID\u2009\u2013\u200910.1016\/j.clml.2026.03.002 [doi]. Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis. To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. (1474\u20135488 (Electronic))"},{"issue":"1","key":"7140_CR100","first-page":"184","volume":"111","author":"D Dima","year":"2026","unstructured":"Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G et al (2026) Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. Haematologica 111(1):184\u2013195","journal-title":"Haematologica"},{"key":"7140_CR101","doi-asserted-by":"crossref","unstructured":"Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T et al (2026) Safety and efficacy of ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma: a CIBMTR study. Blood Cancer J. ;16(1)","DOI":"10.1038\/s41408-026-01605-9"},{"key":"7140_CR102","doi-asserted-by":"crossref","unstructured":"Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C et al (2025) Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood","DOI":"10.1182\/blood.2025028330"},{"issue":"1","key":"7140_CR103","doi-asserted-by":"publisher","first-page":"e70070","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz M, Albici A-M, Tresckow B, Rathje K, Fenk R, Holderried T et al (2025) Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. HemaSphere 9(1):e70070","journal-title":"HemaSphere"},{"key":"7140_CR104","doi-asserted-by":"crossref","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A et al (2025) Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma. J Clin oncology: official J Am Soc Clin Oncol. :JCO2401730","DOI":"10.1016\/S2152-2650(24)01848-2"},{"issue":"1","key":"7140_CR105","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang B-Y, Yu S-H, Chen S-J, Yang S-S, Liu R et al (2024) Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol 17(1):23","journal-title":"J Hematol Oncol"},{"issue":"9","key":"7140_CR106","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","volume":"30","author":"W Wesson","year":"2024","unstructured":"Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E et al (2024) Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. Transplantation Cell therapy 30(9):876\u2013884","journal-title":"Transplantation Cell therapy"},{"issue":"20","key":"7140_CR107","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z et al (2022) Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin oncology: official J Am Soc Clin Oncol 40(20):2246\u20132256","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"7140_CR108","doi-asserted-by":"crossref","unstructured":"Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R et al (2025) Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Haematologica","DOI":"10.3324\/haematol.2025.287985"},{"issue":"1","key":"7140_CR109","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM et al (2023) The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol 16(1):88","journal-title":"J Hematol Oncol"},{"issue":"8","key":"7140_CR110","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","volume":"24","author":"A Oliver-Cald\u00e9s","year":"2023","unstructured":"Oliver-Cald\u00e9s A, Gonz\u00e1lez-Calle V, Caba\u00f1as V, Espa\u00f1ol-Rego M, Rodr\u00edguez-Otero P, Reguera JL et al (2023) Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol 24(8):913\u2013924","journal-title":"Lancet Oncol"},{"issue":"2","key":"7140_CR111","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO et al (2023) Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 29(2):422\u2013429","journal-title":"Nat Med"},{"issue":"4","key":"7140_CR112","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41375-025-02518-5","volume":"39","author":"G Ravi","year":"2025","unstructured":"Ravi G, Richard S, Kumar S, Atrash S, Liedtke M, Kaur G et al (2025) Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T\u00ae Chimeric Antigen Receptor (CAR) T cell therapy CC-98633\/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia 39(4):816\u2013826","journal-title":"Leukemia"},{"issue":"1","key":"7140_CR113","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","volume":"16","author":"J Zhao","year":"2023","unstructured":"Zhao J, Ren Q, Liu X, Guo X, Song Y (2023) Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J Hematol Oncol 16(1):92","journal-title":"J Hematol Oncol"},{"issue":"1","key":"7140_CR114","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"W-H Zhao","year":"2022","unstructured":"Zhao W-H, Wang B-Y, Chen L-J, Fu W-J, Xu J, Liu J et al (2022) Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol 15(1):86","journal-title":"J Hematol Oncol"},{"issue":"2","key":"7140_CR115","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/cid\/ciae291","volume":"79","author":"JA Hill","year":"2024","unstructured":"Hill JA, Martens MJ, Young J-AH, Bhavsar K, Kou J, Chen M et al (2024) SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study. Clin Infect diseases: official publication Infect Dis Soc Am 79(2):542\u2013554","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"18","key":"7140_CR116","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","volume":"7","author":"JS Little","year":"2023","unstructured":"Little JS, Tandon M, Hong JS, Nadeem O, Sperling AS, Raje N et al (2023) Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv 7(18):5485\u20135495","journal-title":"Blood Adv"},{"issue":"6","key":"7140_CR117","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/bloodadvances.2024015008","volume":"9","author":"T Richardson","year":"2025","unstructured":"Richardson T, Sch\u00fctte D, Kobbe G, Baermann B-N, Holderried TAW, Schmitz F et al (2025) Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis. Blood Adv 9(6):1370\u20131375","journal-title":"Blood Adv"},{"issue":"5","key":"7140_CR118","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","volume":"12","author":"J Xia","year":"2025","unstructured":"Xia J, Sun Q, Zhou D, Li H, Wang Y, Qi Y et al (2025) Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol 12(5):e365\u2013e75","journal-title":"Lancet Haematol"},{"key":"7140_CR119","doi-asserted-by":"crossref","unstructured":"Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK et al (2024) EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer. ;12(10)","DOI":"10.1136\/jitc-2024-009220"},{"issue":"6","key":"7140_CR120","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","volume":"29","author":"KR Reyes","year":"2023","unstructured":"Reyes KR, Huang C-Y, Lo M, Arora S, Chung A, Wong SW et al (2023) Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplantation Cell therapy 29(6):350\u2013355","journal-title":"Transplantation Cell therapy"},{"issue":"7","key":"7140_CR121","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"SK Thiruvengadam","year":"2022","unstructured":"Thiruvengadam SK, Sheng Y, Huang C-Y, Bylsma S, Lo M, Kennedy V et al (2022) Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv 6(7):2045\u20132054","journal-title":"Blood Adv"},{"issue":"6","key":"7140_CR122","doi-asserted-by":"publisher","first-page":"304e1","DOI":"10.1016\/j.jtct.2022.03.005","volume":"28","author":"S Josyula","year":"2022","unstructured":"Josyula S, Pont MJ, Dasgupta S, Song X, Thomas S, Pepper G et al (2022) Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. Transplantation Cell therapy 28(6):304e1\u2013e9","journal-title":"Transplantation Cell therapy"},{"issue":"11","key":"7140_CR123","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO-25-01969","volume":"44","author":"W Yan","year":"2026","unstructured":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T et al (2026) Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001). J Clin Oncol 44(11):992\u20131002","journal-title":"J Clin Oncol"},{"issue":"16","key":"7140_CR124","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/bloodadvances.2025016748","volume":"9","author":"JS Little","year":"2025","unstructured":"Little JS, Medina Pena A, Kim EB, Yee AJ, Nadeem O, Midha S et al (2025) Invasive fungal disease is rare in patients with relapsed\/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Blood Adv 9(16):4190\u20134194","journal-title":"Blood Adv"},{"key":"7140_CR125","doi-asserted-by":"crossref","unstructured":"Cohen I, Lebel E, Grisariu S, Avni B, Kfir-Erenfeld S, Asherie N et al (2026) Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy. Int J Mol Sci. ;27(7)","DOI":"10.3390\/ijms27073113"},{"key":"7140_CR126","doi-asserted-by":"crossref","unstructured":"Habib A, Ahmed N, Khan AM, Chang D, Paul B, Shaikh H et al (2026) BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed\/Refractory Multiple Myeloma and Renal Impairment. Curr Oncol. ;33(2)","DOI":"10.3390\/curroncol33020080"},{"key":"7140_CR127","doi-asserted-by":"crossref","unstructured":"Liu KJ, Zhang L, Zhou B, Hong JS, Pak A, Yee AJ et al (2026) Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy. Transpl Cell Ther","DOI":"10.1016\/j.jaci.2024.12.101"},{"issue":"18","key":"7140_CR128","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1182\/bloodadvances.2024013813","volume":"8","author":"SP Hammond","year":"2024","unstructured":"Hammond SP (2024) Defining infection risk of bispecific antibodies for myeloma. Blood Adv 8(18):4977\u20134978","journal-title":"Blood Adv"},{"key":"7140_CR129","doi-asserted-by":"crossref","unstructured":"Lesokhin A, Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA et al (2024) Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma. Res square","DOI":"10.21203\/rs.3.rs-3911922\/v1"},{"issue":"7","key":"7140_CR130","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/bloodadvances.2025017889","volume":"10","author":"LB Julia Mersi","year":"2026","unstructured":"Julia Mersi LB, Xiang Zhou F, Eisele M, Fante C, Riedhammer A, Stich N, Isberner N, Afrin J, Duell MS, Topp H, Einsele J, Waldschmidt K, Martin, Kort\u00fcm (2026) Leo Rasche. Significant burden of low-grade infections in patients treated with T-cell\u2013engaging therapies for multiple myeloma. blood Adv 10(7):2244\u20132248","journal-title":"blood Adv"},{"issue":"3","key":"7140_CR131","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.19244","volume":"204","author":"L Hammons","year":"2024","unstructured":"Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M et al (2024) Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol 204(3):887\u2013891","journal-title":"Br J Haematol"},{"issue":"1","key":"7140_CR132","doi-asserted-by":"publisher","first-page":"e14109","DOI":"10.1111\/tid.14109","volume":"25","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Hall VG, Teh BW (2023) Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl Infect disease: official J Transplantation Soc 25(1):e14109","journal-title":"Transpl Infect disease: official J Transplantation Soc"},{"issue":"1","key":"7140_CR133","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/hem3.70062","volume":"9","author":"S Stock","year":"2025","unstructured":"Stock S, B\u00fccklein VL, Blumenberg V, Magno G, Emhardt A-J, Holzem AME et al (2025) Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma. HemaSphere 9(1):e70062","journal-title":"HemaSphere"},{"issue":"6","key":"7140_CR134","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A et al (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 24(6):e255\u2013e69","journal-title":"Lancet Oncol"},{"issue":"10262","key":"7140_CR135","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M et al (2020) Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet (London England) 396(10262):1563\u20131573","journal-title":"Lancet (London England)"},{"issue":"10292","key":"7140_CR136","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos M-A, Mikhael J, Yong K, Capra M, Facon T et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet (London England) 397(10292):2361\u20132371","journal-title":"Lancet (London England)"},{"issue":"5","key":"7140_CR137","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H et al (2024) Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med 391(5):408\u2013421","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07140-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:02:00Z","timestamp":1789470120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07140-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":137,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7140"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07140-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":5,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"397"}}